These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of superficial transitional cell carcinoma of the bladder. Fleischmann J; Goldberg G Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825 [TBL] [Abstract][Full Text] [Related]
4. Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Brandau S Eur Urol; 2008 Sep; 54(3):629-30. PubMed ID: 18222602 [No Abstract] [Full Text] [Related]
5. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder]. Leibovici D; Zisman A; Lindner A Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074 [No Abstract] [Full Text] [Related]
6. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer. Sosnowski JT Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653 [No Abstract] [Full Text] [Related]
7. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941 [TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
9. BCG in carcinoma in situ and superficial bladder tumors. Lamm DL Prog Clin Biol Res; 1988; 269():497-510. PubMed ID: 3293069 [No Abstract] [Full Text] [Related]
10. [Our experience in the treatment of superficial cancer of the bladder with BCG]. Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959 [TBL] [Abstract][Full Text] [Related]
11. [Trials of immunotherapy in tumors of the urinary tract]. Corrado F; Pizza G Arch Esp Urol; 1984 Dec; 37 Suppl 2():659-66. PubMed ID: 6336141 [No Abstract] [Full Text] [Related]
12. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
13. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304 [TBL] [Abstract][Full Text] [Related]
14. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. Brake M; Loertzer H; Horsch R; Keller H J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163 [TBL] [Abstract][Full Text] [Related]
15. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
16. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. de Reijke TM; de Boer EC; Kurth KH; Schamhart DH J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640 [TBL] [Abstract][Full Text] [Related]